Humulin Nph Kwikpen (Insulin Human (Rdna))

Humulin Nph Kwikpen is used as part of a comprehensive diabetes management plan to provide basal insulin coverage.

• For adults and children with type 1 diabetes mellitus requiring intermediate‑acting insulin.
• For adults with type 2 diabetes mellitus when basal insulin is indicated.
• As a supplement to rapid‑acting insulin analogues to achieve full‑day glucose control.
• In patients who need a predictable, intermediate‑duration insulin effect lasting up to 24 hours.
• Can be combined with oral antidiabetic drugs when additional glucose lowering is required.

• Humulin Nph Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. In the liver, it suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The NPH formulation creates a protamine‑based depot that releases insulin slowly, providing an intermediate‑acting profile lasting roughly 12–24 hours.

The most frequently reported reactions to Humulin Nph Kwikpen involve the injection site and systemic hypoglycaemia, while rare events may be serious.

Common

• Mild hypoglycaemia (blood glucose below 70 mg/dL) that may cause shakiness, sweating, hunger, or difficulty concentrating.
• Injection‑site reactions such as redness, swelling, itching, or a small lump that usually resolve within a few days.
• Lipohypertrophy, a localized thickening of the subcutaneous tissue that can affect insulin absorption if repeated in the same area.
• Transient weight gain often observed during the initial weeks of therapy as glucose utilization improves.

Serious

• Severe hypoglycaemia with loss of consciousness or seizures, requiring assistance from another person or medical intervention.
• Allergic responses ranging from urticaria and angio‑edema to full‑body anaphylaxis, which demand immediate treatment.
• Hypersensitivity manifestations including bronchospasm, severe skin eruption, or serum sickness‑like reactions.

When using Humulin Nph Kwikpen, several precautionary measures should be observed to minimise risk and ensure effective therapy.

• Rotate injection sites within the abdomen, thigh or upper arm to prevent lipohypertrophy.
• Do not use the pen if the insulin appears cloudy, discoloured, or contains particles.
• Store the pen at controlled room temperature; avoid freezing and protect from direct heat or sunlight.
• Check blood glucose before each dose and adjust timing around meals and exercise.
• Discuss pregnancy, lactation, renal or hepatic impairment with a healthcare professional before use.

Humulin Nph Kwikpen may interact with several medicines; awareness of these interactions helps maintain stable glucose control.

Avoid

• Concurrent use of other insulin products or concentrated insulin formulations without dose adjustment.
• Beta‑blockers, which can mask hypoglycaemia symptoms and prolong insulin action.
• Monoamine oxidase inhibitors (MAOIs) that may potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) may increase risk of hypoglycaemia.
• Corticosteroids can raise blood glucose and may require higher insulin doses.
• Thiazide diuretics may cause mild hyperglycaemia, necessitating monitoring.
• Alcohol consumption can enhance insulin’s effect and precipitate hypoglycaemia.